Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of hormone replacement therapy for climacteric symptoms.

Biochemical and biophysical research communications - 3 Oct 2008

Takeo Chikari, Ugai Kanako, Araki Jungo, Zhang Ling, Baba Masanori, Ohashi Wataru, Ueno Koichi, Suzuki Yoichi, Amano Keiko, Hirai Aizan, Muramatsu Masaaki

Abstract excerpt

Hormone replacement therapy (HRT) is highly effective for women suffering from climacteric symptoms, with occasionally severe side effects. To determine which women needs HRT for climacteric symptoms indeed, pharmacogenetical approach for HRT was performed. Under the condition of minimal HRT, 33...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Estradiol
Share to Estrogen Receptor alpha
Share to Estrogen Receptor beta

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Replacement Therapy

Share to Homozygote

Share to Menopause

Share to Pharmacogenetics

Source

Identifiers

PMID: 18627768
DOI: 10.1016/j.bbrc.2008.07.017

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18627768-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of hormone replacement therapy for climacteric symptoms.PMID 18627768Read ↗

Risk-Reducing Salpingo-Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause: Scientific Impact Paper No. 66 October 2021: Scientific Impact Paper No. 66.Semantic proximity Read ↗

Hormone replacement therapy in gynecological cancer survivors and BRCA mutation carriers: a MITO group survey.Semantic proximity Read ↗

Association of estrogen receptor alpha gene microsatellite polymorphism with annual changes in bone mineral density in Korean women with hormone replacement therapy.Semantic proximity Read ↗

Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American Menopause Society.Semantic proximity Read ↗

ESR1 polymorphisms were associated with aromatase inhibitors induced musculoskeletal symptoms in breast cancer patients.Semantic proximity Read ↗

Influence of SULT1A1 genetic variation on age at menopause, estrogen levels, and response to hormone therapy in recently postmenopausal white women.Semantic proximity Read ↗

Hormonal Replacement Therapy Reduces the Severity of Climacteric Symptoms among BRCA Mutation Carriers Who Have Surgical Menopause While Mindfulness-Based Stress Reduction May Evoke Adverse EffectsSemantic proximity Read ↗

Effect of ESR1 and ESR2 polymorphisms on ovarian response in assisted reproductive technology cycles: a systematic review and meta-analysis.Semantic proximity Read ↗

SLCO1B1 genetic variation and hormone therapy in menopausal women.Semantic proximity Read ↗

Polymorphisms in the estrogen synthesis and metabolism pathways and symptoms during the menopausal transition: observations from the Seattle Midlife Women's Health Study.Semantic proximity Read ↗

Use of hormone replacement therapy after risk-reducing salpingo-oophorectomy.Semantic proximity Read ↗

Effect of estrogen receptor gene ESR1 polymorphism on development of premenstrual syndrome.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.